The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- QRx’s Safety Advantage Claim for Moxduo Opiate Combo Is Not A Safe, Well-traveled Route For NDA Apr. 18, 2014
- “Compassionate Use” Bill Would Allow Sale of Unapproved Drugs to Terminally Ill; FDA Has Faced Similar Pressure Before Apr. 16, 2014
- Orphan Drug Designations: FDA Seeks Comments on Naming and Limit for Deficiency Letter Responses Apr. 15, 2014
See More Research Notes